REGENXBIO Inc. (RGNX) Insider Ownership

Historic Insider Ownership Trends

As of March 23, 2026, Regenxbio's top three insider holders are Allan M. Fox (Director, 1.53Mn shares), Kenneth T. Mills (Director, 486.12K shares), Curran Simpson (Chief Executive Officer, 342.47K shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares (Direct) Shares (Indirect) Report Date
Allan M. Fox 0 1,529,981 27 Dec, 2021
Kenneth T. Mills 486,118 0 29 Jan, 2026
Curran Simpson Chief Executive Officer 342,467 0 08 Jan, 2026
Steve Pakola Chief Medical Officer 253,050 0 03 Feb, 2026
Steve Pakola Chief Medical Officer 247,926 0 12 Mar, 2026
Vittal Vasista Chief Financial Officer 246,534 0 21 Mar, 2024
Olivier Danos Chief Scientific Officer 226,348 0 04 Apr, 2025
Mitchell Chan Chief Financial Officer 127,717 0 08 Jan, 2026
Craig Malzahn Chief Technology Officer 82,194 0 08 Jan, 2026
Jennifer Zachary 22,064 0 03 Jun, 2025
Jean Bennett 19,054 0 03 Jun, 2025
Alexandra Glucksmann 19,054 0 03 Jun, 2025
David C Stump 19,054 0 03 Jun, 2025
Daniel Tasse 19,054 0 03 Jun, 2025
Allan M. Fox 19,054 0 03 Jun, 2025

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
10 Mar, 2026 Steve Pakola Common Stock D 5,124 $10.35 247,926 D S
01 Feb, 2026 Steve Pakola Common Stock D 5,267 $11.16 253,050 D F
01 Feb, 2026 Steve Pakola Common Stock D 5,267 $11.16 253,050 D F
27 Jan, 2026 Kenneth T. Mills Common Stock A 225,000 $13.09 707,871 D M
27 Jan, 2026 Kenneth T. Mills Common Stock D 221,753 $13.41 486,118 D F
27 Jan, 2026 Kenneth T. Mills Stock Options (Right to Buy) D 225,000 $0.00 225,000 D M
06 Jan, 2026 Craig Malzahn Common Stock A 65,847 $0.00 82,194 D A
06 Jan, 2026 Mitchell Chan Common Stock A 73,749 $0.00 127,717 D A
06 Jan, 2026 Curran Simpson Common Stock A 144,864 $0.00 342,467 D A
06 Jan, 2026 Steve Pakola Common Stock A 65,847 $0.00 258,317 D A
06 Jan, 2026 Steve Pakola Common Stock A 65,847 $0.00 258,317 D A
06 Jan, 2026 Steve Pakola Stock Options (Right to buy) A 35,402 $0.00 35,402 D A
06 Jan, 2026 Mitchell Chan Stock Options (Right to buy) A 39,650 $0.00 39,650 D A
06 Jan, 2026 Craig Malzahn Stock Options (Right to buy) A 35,402 $0.00 35,402 D A
06 Jan, 2026 Curran Simpson Stock Options (Right to buy) A 233,651 $0.00 233,651 D A
06 Jan, 2026 Steve Pakola Stock Options (Right to buy) A 35,402 $0.00 35,402 D A
02 Jan, 2026 Steve Pakola Common Stock D 18,247 $14.40 192,470 D F
02 Jan, 2026 Craig Malzahn Common Stock D 1,238 $14.40 16,347 D F
02 Jan, 2026 Curran Simpson Common Stock D 18,559 $14.40 197,603 D F
02 Jan, 2026 Steve Pakola Common Stock D 18,247 $14.40 192,470 D F